Ms. Regina Groves's most recent trade in Atricure Inc was a trade of 5,313 Common Stock done at an average price of $54.2 . Disclosure was reported to the exchange on Sept. 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atricure Inc | Ms. Regina E. Groves | Director | Sale of securities on an exchange or to another person at price $ 54.22 per share. | 11 Sep 2026 | 5,313 | 34,546 (0%) | 0% | 54.2 | 288,071 | Common Stock |
| Atricure Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2026 | 6,144 | 39,859 (0%) | 0% | 0 | Common Stock | |
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 11,117 | 28,099 (0%) | 0% | 0 | Common Stock | |
| Atricure Inc | Ms. Regina E. Groves | Director | Sale of securities on an exchange or to another person at price $ 36.82 per share. | 06 Aug 2025 | 2,452 | 33,715 (0%) | 0% | 36.8 | 90,283 | Common Stock |
| Atricure Inc | Ms. Regina Groves | Director | Sale of securities on an exchange or to another person at price $ 36.82 per share. | 06 Aug 2025 | 2,452 | 33,715 (0%) | 0% | 36.8 | 90,283 | - |
| Atricure Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 5,401 | 36,167 (0%) | 0% | 0 | Common Stock | |
| Atricure Inc | Ms. Regina Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 5,401 | 36,167 (0%) | 0% | 0 | - | |
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 8,982 | 16,982 (0%) | 0% | 0 | Common Stock | |
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | 16 May 2024 | 5,481 | 5,481 | - | - | Stock Option (Right to Buy) | ||
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 4,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Atricure Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 7,788 | 30,766 (0%) | 0% | 0 | Common Stock | |
| Atricure Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 3,186 | 22,978 (0%) | 0% | 0 | Common Stock | |
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | 18 May 2023 | 6,759 | 6,759 | - | - | Stock Option (Right to Buy) | ||
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Fulgent Genetics Inc | Ms. Regina E. Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 4,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| Atricure Inc | Ms. Regina Groves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 3,564 | 19,792 (0%) | 0% | 0 | Common Stock |